6Panwels R A, Buist A S, Calverley P M, et al. Global strategy for the di- agnosis, management, and prevention of chronic obstructive pulmonary disease, NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease( GOLD ) Workshop summary . Am J Respir Crit Care Med, 2001, 163(5): 1256.
7Blats L, Bourbbeau J, Sheehy O, et al. Inhaled corticosteroids inCOPD: deter minants of use and trends in patient persistence with treatment. Can Respir J,2004,11 ( 1 ) :27.
8Eickelberg U, RothM, Lorx R, et al. Ligand - independent activation of the glucocorticoid receptor by beta2 - adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle ceils. J Bio Chen, 1999, 274(2): 1005.
9Canis R, Demirkok S S, Osar Z, et al. Effects of inhaled budesonide on insulin sensitivity in nondiabetic patients with asthma and chronic ob- structive oulmonarv disease . Adv Ther. 2007. 24(3) :560.
10Decram er M, Fergu son G. Clinical safety of long acting beta2 - agonist and inhaled cortisterroid combination therapy in COPD . COPD, 2006, 3 (3) :163.
